Aryl-substituted polycyclic amines, method for the production thereof, and use thereof as a medicament

• US 7,838,547 B2
• Filed: 02/13/2007
• Issued: 11/23/2010
• Est. Priority Date: 08/16/2004
• Status: Expired due to Fees

• Current Assignee: Sanofi-Aventis Deutschland GmbH (Sanofi )
• Original Assignee: Sanofi-Aventis Deutschland GmbH (Sanofi )
• Inventors: Lenning, Petra, Schwink, Lothar, Hessler, Gerhard, Stengelin, Siegfried, Gossel, Matthias
• Primary Examiner(s): Loewe; Sun Jae Y.
• Application Number:
  US11/674,353
• Publication Number:
  US 20070299077A1
• Time in Patent Office: 1,379 Days
• Field of Search: None
• US Class Current: 514/412
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/12 Antihypertensives
• CPC Class Codes: C07D 471/04 Ortho-condensed systems
• CPC Class Codes: C07D 471/08 Bridged systems
• CPC Class Codes: C07D 487/04 Ortho-condensed systems

Abstract

The invention relates to aryl-substituted polycyclic amines of formula I, especially bicyclic amines, and to the physiologically tolerated salts and physiologically functional derivatives thereof;

where the symbols and radicals are explained in the description, as well as to pharmaceutical compositions containing them and to methods of treatment using them.

Claims

1. A compound of formula I:

2. The compound as claimed in claim 1, wherein Q is selected from:

3. The compound as claimed in claim 1, wherein

K is a bond, O, CO, OCH₂, CH₂O, N(R36)CO, or CON(R37);

and wherein

R36, and R37 are, independently of one another, H or (C₁-C₈)-alkyl.

4. The compound as claimed in claim 1, wherein

R2 is selected from the group consisting of n-propyl, n-butyl, iso-butyl, iso-pentyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohex-1-enyl, phenyl, p-fluorophenyl, p-chlorophenyl, p-bromophenyl, p-tolyl, p-methoxyphenyl and p-trifluoromethylphenyl.

5. The compound as claimed in claim 1, wherein

A, B, D, and G are C(R3), and wherein

R3 is H, F, or (C₁-C₆)-alkyl.

6. The compound as claimed in claim 1, wherein X is a bond or N(R16), in which R16 is H or (C₁-C₈)-alkyl.

7. A pharmaceutical composition comprising one or more of the compounds of formula I as claimed in claim 1.